5'-deoxy-5-fluorouridine + etoposide + medroxyprogesterone acetate + mitomycin C

This is a multi-agent chemotherapy combination consisting of four drugs: - **5'-deoxy-5-fluorouridine** (an oral prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase and disrupts DNA synthesis) - **Etoposide** (a topoisomerase II inhibitor that causes DNA strand breaks) - **Medroxyprogesterone acetate** (a synthetic progestin with antineoplastic and hormonal activity, used in hormone-sensitive cancers; it acts primarily via the progesterone receptor to inhibit gonadotropin production and reduce estrogen-driven cell proliferation[3][7]) - **Mitomycin C** (an antitumor antibiotic that acts as a bifunctional alkylating agent after activation, cross-linking DNA and inhibiting its synthesis[6][8][10]) This combination is designed for synergistic cytotoxic effects against cancer cells by targeting multiple pathways involved in cell division, hormone signaling, and DNA integrity. Such regimens are typically investigated or used for advanced or refractory cancers where multi-modal mechanisms are desired.